These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 31884128)
21. Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC). Elamin YY; Gomez DR; Antonoff MB; Robichaux JP; Tran H; Shorter MK; Bohac JM; Negrao MV; Le X; Rinsurogkawong W; Lewis J; Lacerda L; Roarty EB; Swisher SG; Roth JA; Zhang J; Papadimitrakopoulou V; Heymach JV Clin Lung Cancer; 2019 Jan; 20(1):43-47. PubMed ID: 30343004 [TBL] [Abstract][Full Text] [Related]
22. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation. Chantharasamee J; Poungvarin N; Danchaivijitr P; Techawatanawanna S BMC Cancer; 2019 Jul; 19(1):701. PubMed ID: 31315599 [TBL] [Abstract][Full Text] [Related]
23. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project. Beau-Faller M; Pencreach E; Leduc C; Blons H; Merlio JP; Bringuier PP; de Fraipont F; Escande F; Lemoine A; Ouafik L; Denis M; Hofman P; Lacave R; Melaabi S; Langlais A; Missy P; Morin F; Moro-Sibilot D; Barlesi F; Cadranel J; Lung Cancer; 2020 Feb; 140():19-26. PubMed ID: 31841714 [TBL] [Abstract][Full Text] [Related]
24. Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer. Rossi S; Finocchiaro G; Noia VD; Bonomi M; Cerchiaro E; Rose F; Franceschini D; Navarria P; Ceresoli GL; Beretta GD; D'Argento E; Scorsetti M; Santoro A; Toschi L Future Oncol; 2019 Nov; 15(33):3775-3782. PubMed ID: 31709807 [No Abstract] [Full Text] [Related]
25. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation. Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455 [TBL] [Abstract][Full Text] [Related]
26. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation. Yoshida T; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y; Goto K Lung Cancer; 2015 Dec; 90(3):477-83. PubMed ID: 26604031 [TBL] [Abstract][Full Text] [Related]
28. Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs. Takeda M; Sakai K; Hayashi H; Tanaka K; Haratani K; Takahama T; Kato R; Yonesaka K; Nishio K; Nakagawa K Lung Cancer; 2020 Jan; 139():28-34. PubMed ID: 31710890 [TBL] [Abstract][Full Text] [Related]
29. Overlap time is an independent risk factor of radiation pneumonitis for patients treated with simultaneous EGFR-TKI and thoracic radiotherapy. Jia W; Gao Q; Wang M; Li J; Jing W; Yu J; Zhu H Radiat Oncol; 2021 Feb; 16(1):41. PubMed ID: 33622352 [TBL] [Abstract][Full Text] [Related]
30. Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. Matsumoto Y; Sawa K; Fukui M; Oyanagi J; Yoshimoto N; Suzumura T; Watanabe T; Kaneda H; Mitsuoka S; Asai K; Kimura T; Yamamoto N; Hirata K; Koh Y; Kawaguchi T Lung Cancer; 2020 Jan; 139():80-88. PubMed ID: 31751804 [TBL] [Abstract][Full Text] [Related]
31. Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases. Flippot R; Biondani P; Auclin E; Xiao D; Hendriks L; Le Rhun E; Leduc C; Beau-Faller M; Gervais R; Remon J; Adam J; Planchard D; Lavaud P; Naltet C; Caramella C; Le Pechoux C; Lacroix L; Gazzah A; Mezquita L; Besse B J Thorac Oncol; 2019 Aug; 14(8):1400-1407. PubMed ID: 31108248 [TBL] [Abstract][Full Text] [Related]
32. Clinical Implications of Isolated Bone Failure Without Systemic Disease Progression During EGFR-TKI Treatment. Hwang JA; Lee JY; Kim WS; Song JS; Rho JK; Choi CM; Lee JC Clin Lung Cancer; 2016 Nov; 17(6):573-580.e1. PubMed ID: 27378173 [TBL] [Abstract][Full Text] [Related]
33. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation. Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841 [TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes in patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer in South Western Sydney Local Health District. Ding PN; Roberts TL; Chua W; Becker TM; Descallar J; Yip PY; Bray V Intern Med J; 2017 Dec; 47(12):1405-1411. PubMed ID: 28742280 [TBL] [Abstract][Full Text] [Related]
35. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma. Chen Y; Yang J; Li X; Hao D; Wu X; Yang Y; He C; Wang W; Wang J Cancer Sci; 2016 Dec; 107(12):1800-1805. PubMed ID: 27627582 [TBL] [Abstract][Full Text] [Related]
36. Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations. Kogure Y; Saka H; Oki M; Saito TI; Ahmed SN; Kitagawa C; Imaizumi K PLoS One; 2015; 10(8):e0135393. PubMed ID: 26262682 [TBL] [Abstract][Full Text] [Related]
37. Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first-line gefitinib therapy: a single-institute retrospective study. Kashiwabara K; Fujii S; Tsumura S; Sakamoto K J Cancer Res Clin Oncol; 2021 Jan; 147(1):287-293. PubMed ID: 32761377 [TBL] [Abstract][Full Text] [Related]
38. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. Yu HA; Sima CS; Huang J; Solomon SB; Rimner A; Paik P; Pietanza MC; Azzoli CG; Rizvi NA; Krug LM; Miller VA; Kris MG; Riely GJ J Thorac Oncol; 2013 Mar; 8(3):346-51. PubMed ID: 23407558 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations. Imai H; Minemura H; Sugiyama T; Yamada Y; Kaira K; Kanazawa K; Kasai T; Kaburagi T; Minato K; Cancer Chemother Pharmacol; 2018 Jul; 82(1):119-127. PubMed ID: 29737372 [TBL] [Abstract][Full Text] [Related]
40. Number of metastatic organs negatively affects the treatment sequence in patients with EGFR-TKI failure. Mizuno T; Horinouchi H; Watanabe S; Sato J; Morita R; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Ohe Y Thorac Cancer; 2020 Apr; 11(4):1038-1044. PubMed ID: 32077630 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]